Sites & Styles

Thursday, March 22

18:30 - drinks and dinner

Please meet in the lobby of the Manchester Business School, and we will then head to a nearby restaurant for drinks and dinner.

Friday, March 23

10:00-12:00

(1) Trials within and across boundaries; making connections across contrasting sites

What do people on either side of the Atlantic, for example, think about trials on the other side? How have trials in one side influenced trials organized elsewhere. How did protocols travel? And by taking this comparative perspective, can we say anything new about cancer trials?

Discussion papers

• Alberto Cambrosio (McGill University) and Peter Keating (University of Quebec, Montreal)
• Gerald Kutcher (Binghamton University)
• Ornella Moscucci (London School of Hygiene and Tropical Medicine)
• Helen Valier (University of Houston)
• Discussant: Emm Barnes
  

12:00-13:15 - lunch

13:15-15:00

(2) Leading and trailing cancers; comparisons and connections

Certain forms of treatment have been models for the treatment of other cancers at different points in time and in different places. What turns one form of malignant disease (and its treatment) into a model? How have ideas about 'advance' and 'stagnation' shaped cancer research and treatment?

Discussion papers

• Emm Barnes (University of Manchester)
• Gretchen Krueger (Senior Historian, Wells Fargo & Co, San Francisco)
• Carsten Timmermann (University of Manchester)
• Discussant: Helen Valier
  

15:00-15:30 - coffee and tea break

15:30-17:30

(3) Rethinking risk

What can we as historians and historically-minded social scientists say about cancer and risk that is new? What does historicizing 'cancer risk' add to our (and others') understanding of cancer and risk generally?

Discussion papers

• Robert Aronowitz (University of Pennsylvania, Philadelphia)
• Linda Bryder (University of Auckland)
• Ilana Löwy (CERMES, Paris)
• Toine Pieters and Stephen Snelders (Vrije Universiteit Amsterdam)
• Discussant: Elizabeth Toon
  

19:30 - dinner (location and directions to be announced)

Saturday, March 24

9:00-11:00

(4) Screening within and across boundaries

How have screening programmes institutionalized perceptions of risk and attitudes towards prevention? What do different national attitudes and approaches to cancer screening reveal? How is evidence about screening deployed in different contexts? How have international debates about screening resembled and differed from international debates about treatment and trials?

Discussion papers

• Bettina Borisch (University of Geneva)
• David Cantor (NLM/NCI)
• Christine Holmberg (NCI)
• Elizabeth Toon (University of Manchester)
• Discussant: Carsten Timmermann
  

11:00-11:30 - coffee and tea break

(5) Modalities and nations

We are proposing a general discussion on the relationships of surgery, radiotherapy and chemotherapy in the US, UK, France and Sweden. What determined the relative development of the modalities in different countries? How did those histories structure later services? How do the histories relate to cancer services and policies now?

Discussion papers

• John Pickstone (University of Manchester)
• Barbara Bridgman Perkins (Healthcare Consultant, Washington DC)
• Discussant: Ilana Löwy
  

13:00-14:30 - lunch

14:30-16:15

(6) Policies and centre-periphery relations in post war France

How did radiotherapy develop after WWII? What were its new relations with surgery and with haematology and medical oncology? How was the position of the centres challenged by other sites, from elite research institutions to ordinary general hospitals? We would hope that the discussion will then broaden to involve comparisons with present day services in North America, Europe, and elsewhere.

Discussion papers

• Patrick Castel (CSO, Paris)
• Patrice Pinell (INSERM, Paris)
• Francois Briatte (University of Edinburgh)
• Discussant: John Pickstone